Dr. Shiller on Next-Generation Sequencing in GI Cancers

Shirley Michelle Shiller, DO
Published: Thursday, Sep 20, 2018



Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing (NGS) in gastrointestinal malignancies.

NGS was launched around 2011, and at that time, most people in the field were still doing single-gene testing, says Shiller. She says that this was due to the power of NGS not being fully understood. NGS requires less tissue, and allows for the interpretation of multiple genes at one time. If a patient is very sick, Shiller says that NGS can answer multiple questions at one time with one tissue source. It is also more sensitive.

There has been a shift in recent years toward using NGS. Single-gene assays do still exist, but require more DNA than most of the NGS-based assays, explains Shiller. Two of the significant molecular aberrations to identify in gastrointestinal cancers are mismatch repair deficiency and microsatellite instability, as they can guide treatment decision.


Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing (NGS) in gastrointestinal malignancies.

NGS was launched around 2011, and at that time, most people in the field were still doing single-gene testing, says Shiller. She says that this was due to the power of NGS not being fully understood. NGS requires less tissue, and allows for the interpretation of multiple genes at one time. If a patient is very sick, Shiller says that NGS can answer multiple questions at one time with one tissue source. It is also more sensitive.

There has been a shift in recent years toward using NGS. Single-gene assays do still exist, but require more DNA than most of the NGS-based assays, explains Shiller. Two of the significant molecular aberrations to identify in gastrointestinal cancers are mismatch repair deficiency and microsatellite instability, as they can guide treatment decision.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x